

Perioperative Care of the Patient with Cancer

(2024-2027)

REFERENCES

1. Sullivan, R., et al., *Global cancer surgery: delivering safe, affordable, and timely cancer surgery*. *Lancet Oncol*, 2015. **16**(11): p. 1193-224.
2. Daly JM, D.J., *Principles of surgical oncology*, in *Medical Oncology*, S.P. Calabrese P, Rosenberg SA, , Editor. 1985, Macmillan: Toronto, Canada. p. 261.
3. KR, F., *Surgery in the patient with cancer*, in *Perioperative Medicine: Medical Care of the Surgical Patient*, B.F. Goldmann DR, Guarnieri DM, Editor. 1994, McGraw-Hill: New York, NY. p. 283-293.
4. Sahai, S. and H. Ismail, *Perioperative Implications of Neoadjuvant Therapies and Optimization Strategies for Cancer Surgery*. *Current Anesthesiology Reports*, 2015. **5**(3): p. 305-317.
5. Fleisher, L.A., et al., *2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery*. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2014. **64**(22): p. e77-e137.
6. Halvorsen, S., et al., *2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)*. *European Heart Journal*, 2022. **43**(39): p. 3826-3924.
7. Smilowitz, N.R. and J.S. Berger, *Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review*. *Jama*, 2020. **324**(3): p. 279-290.
8. Douketis, J.D., et al., *Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline*. *Chest*, 2022. **162**(5): p. e207-e243.
9. Sahai, S.K., et al., *Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement*. *Mayo Clin Proc*, 2022. **97**(9): p. 1734-1751.
10. Bdair, F.M., et al., *Gemcitabine and acute myocardial infarction--a case report*. *Angiology*, 2006. **57**(3): p. 367-71.

11. Khakoo, A.Y. and E.T. Yeh, *Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy*. Nat Clin Pract Oncol, 2008. **5**(11): p. 655-67.
12. Gharib, M.I. and A.K. Burnett, *Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis*. Eur J Heart Fail, 2002. **4**(3): p. 235-42.
13. Chu, T.F., et al., *Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib*. Lancet, 2007. **370**(9604): p. 2011-9.
14. Ewer MS, B.R., *Cardiac complications*, in *Cancer Medicine*, K.D. Bast RC, Pollock RE, Editor. 2000, B.C. Decker, Inc: London. p. 2324-2339.
15. Zambetti, M., et al., *Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation*. J Clin Oncol, 2001. **19**(1): p. 37-43.
16. Ando, M., et al., *Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation*. Bone Marrow Transplant, 2000. **25**(2): p. 185-9.
17. Kaur, A., et al., *Thalidomide-induced sinus bradycardia*. Ann Pharmacother, 2003. **37**(7-8): p. 1040-3.
18. Wilke, A., et al., *Elevation of the pacing threshold: a side effect in a patient with pacemaker undergoing therapy with doxorubicin and vincristine*. Oncology, 1999. **56**(2): p. 110-1.
19. Adams, M.J., et al., *Radiation-associated cardiovascular disease*. Crit Rev.Oncol.Hematol., 2003. **45**(1): p. 55-75.
20. Basavaraju, S.R. and C.E. Easterly, *Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications*. Med.Phys., 2002. **29**(10): p. 2391-2403.
21. Kelly, K., et al., *Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors*. Target Oncol, 2009. **4**(2): p. 99-105.
22. Lombardi, G., et al., *Diagnosis and Treatment of Malignant Pleural Effusion: A Systematic Literature Review and New Approaches*. Am J Clin Oncol, 2009.
23. Tashiro, M., et al., *Lung fibrosis 10 years after cessation of bleomycin therapy*. Tohoku J Exp Med, 2008. **216**(1): p. 77-80.
24. Einhorn, L., et al., *Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer*. Cancer, 1976. **37**(5): p. 2414-6.

25. Carver, J.R., et al., *American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects*. Journal of Clinical Oncology, 2007. **25**(25): p. 3991-4008.
26. Sekine, Y., et al., *Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease*. Jpn.J.Thorac.Cardiovasc.Surg., 2005. **53**(5): p. 237-243.
27. Samama, C.M., et al., *Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003*. Minerva Anesthesiol, 2006. **72**(6): p. 447-52.
28. Etchill, E.W., et al., *Platelet Transfusion in Critical Care and Surgery: Evidence-Based Review of Contemporary Practice and Future Directions*. Shock, 2017. **47**(5): p. 537-549.
29. Aapro, M., et al., *Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines*. Annals of Oncology, 2018. **29**: p. iv96-iv110.
30. Shander, A., et al., *Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)*. Annals of Surgery, 2023. **277**(4): p. 581-590.
31. Devon, K.M. and R.S. McLeod, *Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery*. Cochrane Database Syst Rev, 2009(1): p. Cd007148.
32. Carson, J.L., et al., *Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion*. Cochrane Database Syst Rev, 2016. **10**: p. Cd002042.
33. Roubinian, N. and J.L. Carson, *Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy*. Hematol Oncol Clin North Am, 2016. **30**(3): p. 529-40.
34. Cata, J.P., *Perioperative Anemia and Blood Transfusions in Patients with Cancer: When the Problem, the Solution, and Their Combination Are Each Associated with Poor Outcomes*. Anesthesiology, 2015. **122**(1): p. 3-4.
35. Bauhofer, A., et al., *Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial*. Surgery, 2007. **141**(4): p. 501-10.
36. Schaefer, H., et al., *Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial*. Ann Surg, 2004. **240**(1): p. 68-75.
37. Lyman, G.H. and M. Shayne, *Granulocyte colony-stimulating factors: finding the right indication*. Curr Opin Oncol, 2007. **19**(4): p. 299-307.
38. Massey, E., et al., *Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction*. Cochrane Database Syst Rev, 2009(1): p. CD005341.

39. Bratzler, D.W. and D.R. Hunt, *The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery*. Clin Infect Dis, 2006. **43**(3): p. 322-30.
40. Spring, J. and L. Munshi, *Hematology Emergencies in Adults With Critical Illness*. Chest, 2022. **162**(1): p. 120-131.
41. Koretz, M.J. and J.P. Neifeld, *Emergency surgical treatment for patients with acute leukemia*. Surg Gynecol Obstet, 1985. **161**(2): p. 149-51.
42. Groeben, H., A. Heyll, and J. Peters, *[Pathophysiologic and anesthesiologic characteristics of patients with leukemia]*. Anaesthesist, 1992. **41**(8): p. 438-47.
43. Key, N.S., et al., *Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update*. J Clin Oncol, 2023. **41**(16): p. 3063-3071.
44. Streiff, M.B., et al., *Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology*. Journal of the National Comprehensive Cancer Network, 2021. **19**(10): p. 1181-1201.
45. Stevens, S.M., et al., *Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report*. Chest, 2021. **160**(6): p. e545-e608.
46. Lyman, G.H., et al., *Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update*. J Oncol Pract, 2015. **11**(3): p. e442-4.
47. Grigorian, A. and C.B. O'brien, *Hepatotoxicity secondary to chemotherapy*. Journal of Clinical and Translational Hepatology, 2014. **2**(2): p. 95-102.
48. Chun, Y.S., et al., *Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases*. Lancet Oncol, 2009. **10**(3): p. 278-86.
49. Stohr, W., et al., *Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system*. Pediatr Blood Cancer, 2007. **48**(2): p. 140-7.
50. Kintzel, P.E., *Anticancer drug-induced kidney disorders*. Drug Saf, 2001. **24**(1): p. 19-38.
51. Lajer, H., et al., *Magnesium and potassium homeostasis during cisplatin treatment*. Cancer Chemother Pharmacol, 2005. **55**(3): p. 231-6.
52. Lajer, H. and G. Daugaard, *Cisplatin and hypomagnesemia*. Cancer Treat Rev, 1999. **25**(1): p. 47-58.
53. Jones, D.P., et al., *Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group*. Pediatr Blood Cancer, 2008. **51**(6): p. 724-31.

54. El-Hajj Fuleihan, G., et al., *Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline*. The Journal of Clinical Endocrinology & Metabolism, 2022. **108**(3): p. 507-528.
55. Ventola, C.L., *Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations*. P & T : a peer-reviewed journal for formulary management, 2017. **42**(7): p. 452-463.
56. Varricchi, G., et al., *Cardiotoxicity of immune checkpoint inhibitors*. ESMO open, 2017. **2**(4): p. e000247-e000247.
57. Zhang, Y., et al., *Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies*. J Clin Med, 2023. **12**(19).
58. Puckrin, R., K. Jamani, and V.H. Jimenez-Zepeda, *Long-term survivorship care after CAR-T cell therapy*. Eur J Haematol, 2024. **112**(1): p. 41-50.
59. Kearon, C., et al., *Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report*. Chest, 2016. **149**(2): p. 315-352.
60. Ambiru, S., et al., *Poor postoperative blood glucose control increases surgical site infections after surgery for hepato-biliary-pancreatic cancer: a prospective study in a high-volume institute in Japan*. J Hosp Infect, 2008. **68**(3): p. 230-3.
61. Nieto, A., et al., *Determinants of wound infections after surgery for breast cancer*. Zentralbl Gynakol, 2002. **124**(8-9): p. 429-33.
62. Shiono, S., et al., *Risk factors of postoperative respiratory infections in lung cancer surgery*. J Thorac Oncol, 2007. **2**(1): p. 34-8.
63. Uchiyama, K., et al., *Prevention of postoperative infections by administration of antimicrobial agents immediately before surgery for patients with gastrointestinal cancers*. Hepatogastroenterology, 2007. **54**(77): p. 1487-93.
64. Okabayashi, T., et al., *Risk factors and predictors for surgical site infection after hepatic resection*. J Hosp Infect, 2009. **73**(1): p. 47-53.
65. Valentini, V., et al., *Diabetes as main risk factor in head and neck reconstructive surgery with free flaps*. J Craniofac Surg, 2008. **19**(4): p. 1080-4.
66. Warren, A.G., et al., *Lymphedema: a comprehensive review*. Ann Plast Surg, 2007. **59**(4): p. 464-72.
67. Sahai, S.K., A. Zalpour, and M.A. Rozner, *Preoperative evaluation of the oncology patient*. Anesthesiol Clin, 2009. **27**(4): p. 805-22.
68. Casey, A.L. and T.S. Elliott, *Progress in the prevention of surgical site infection*. Curr Opin Infect Dis, 2009. **22**(4): p. 370-5.

69. Deshaies, I., et al., *Antiangiogenic agents and late anastomotic complications*. J Surg Oncol, 2009.